Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Pegvisomant Pregnancy and Breastfeeding Warnings

Pegvisomant is also known as: Somavert

Medically reviewed by Drugs.com. Last updated on Dec 7, 2018.

Pegvisomant Pregnancy Warnings

Pegvisomant has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. Pegvisomant is only recommended for use during pregnancy when benefits outweighs risk.

See references

Pegvisomant Breastfeeding Warnings

There are no data on the excretion of pegvisomant into human milk. The manufacturer recommends that caution be used when administering pegvisomant to nursing women.

See references

References for pregnancy information

  1. "Product Information. Somavert (pegvisomant)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. TGA. Therapeutic Goods Administration. Australian Drug Evaluation Committee "Prescribing medicines in pregnancy: an Australian categorisation of risk of drug use in pregnancy. Available from: URL: http://www.tga.gov.au/docs/html/medpreg.htm." ([1999]):
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. "Product Information. Somavert (pegvisomant)." Pharmacia and Upjohn, Kalamazoo, MI.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide